Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment | Zendy

Pilar María Samper Ots | Zendy; Concepción López Carrizosa | Zendy; Aurora Rodríguez Pérez | Zendy; Juan de Dios Sáez Garrido | Zendy; José María Delgado Pérez | Zendy

Open Access

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment

Author(s) -

Pilar María Samper Ots,

Concepción López Carrizosa,

Aurora Rodríguez Pérez,

Juan de Dios Sáez Garrido,

José María Delgado Pérez

Publication year - 2008

Publication title -

clinical medicine oncology

Language(s) - English

Resource type - Journals

ISSN - 1177-9314

DOI - 10.4137/cmo.s510

Subject(s) - medicine , anemia , darbepoetin alfa , epoetin alfa , radiation therapy , erythropoietin , hemoglobin , gastroenterology , cancer , bone marrow suppression , chemoradiotherapy , surgery , chemotherapy

Anemia is the most frequent hematological disturbance in cancer patients, with prevalence between 30% and 90%, depending on the type of tumor, the antitumor treatment, and other factors (infection, malnutrition, bleeding, tumor infiltration of the bone marrow). A number of erythropoietic agents have shown to be effective in increasing the hemoglobin (Hb) levels, reducing the requirements for transfusion, and improving quality of life. The objective of this study is to compare darbepoetin alfa and epoetin alfa when used to correct anemia in cancer patients who are receiving radiotherapy or radiochemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research